Advertisement
Logo
Search for

Volume 149, Issue 4, Pages 661-671.e1 (April 2010)


View previous. 23 of 40 View next.

Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension

L. Jay KatzaCorresponding Author Informationemail address, John S. Cohenb, Amy L. Batoosinghc, Carlos Felixc, Vincent Shuc, Rhett M. Schiffmanc

Accepted 1 December 2009.

Purpose

To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of ophthalmic formulations of bimatoprost 0.01% and 0.0125% compared with bimatoprost 0.03%.

Design

Prospective, randomized, double-masked, multicenter clinical trial.

Methods

Patients with glaucoma or ocular hypertension were randomized to receive once-daily bimatoprost 0.01% (n = 186), bimatoprost 0.0125% (n = 188), or bimatoprost 0.03% (n = 187) for 12 months. The primary efficacy measure was IOP. Safety measures included adverse events and an objective assessment of conjunctival hyperemia.

Results

Baseline mean IOPs were similar among treatment groups. Differences in mean IOP between the bimatoprost 0.01% or 0.0125% groups and the bimatoprost 0.03% group were less than 0.9 mm Hg throughout follow-up. Bimatoprost 0.01%, but not bimatoprost 0.0125%, was equivalent in efficacy to bimatoprost 0.03% based on predetermined criteria (limits of the 95% confidence interval of the between-group difference in mean IOP within ± 1.5 mm Hg at all time points and within ± 1 mm Hg at most time points). The overall incidence of treatment-related adverse events was reduced significantly in the bimatoprost 0.01% and bimatoprost 0.0125% groups compared with the bimatoprost 0.03% group (P ≤ .034). The percentage of patients with a moderate to severe increase from the baseline macroscopic hyperemia score was: bimatoprost 0.01%, 3.2%; bimatoprost 0.0125%, 9.0%; bimatoprost 0.03%, 9.1% (P = .019 for bimatoprost 0.01% vs 0.03%).

Conclusions

Bimatoprost 0.01% was equivalent to bimatoprost 0.03% in lowering IOP throughout 12 months of treatment and demonstrated improved tolerability, including less frequent and severe conjunctival hyperemia. Bimatoprost 0.01% demonstrated a better benefit-to-risk ratio than bimatoprost 0.0125%.

a Wills Eye Hospital, Philadelphia, Pennsylvania

b Cincinnati Eye Institute, Cincinnati, Ohio

c Allergan, Inc, Irvine, California

Corresponding Author InformationInquiries to L. Jay Katz, Glaucoma Service, Wills Eye Hospital, 840 Walnut Street, Suite 1110, Philadelphia, PA 19107

PII: S0002-9394(09)00906-4

doi:10.1016/j.ajo.2009.12.003


View previous. 23 of 40 View next.

Advertisement